Step 1 topics → General Pharmacology → Serotonin Syndrome, NMS, Malignant Hyperthermia

Serotonin Syndrome, NMS, Malignant Hyperthermia

USMLE Step 1 trap: Confuses the neuromuscular findings of serotonin syndrome (clonus/hyperreflexia) with NMS (lead-pipe rigidity). Serotonin syndrome causes hyperreflexia and clonus (lower extremity > upper), while NMS causes 'lead-pipe' rigidity without clonus.

Serotonin syndrome (SS), neuroleptic malignant syndrome (NMS), and malignant hyperthermia (MH) are three drug-induced hyperthermic emergencies that USMLE Step 1 loves to test together — precisely because students confuse them. All three share hyperthermia and altered mental status, but the triggers, neuromuscular findings, and treatments are distinct. The exam will give you a clinical vignette with a drug history and ask you to identify the syndrome, explain the mechanism, or select the correct treatment. Getting this right means recognizing which drug class caused it and which physical findings are present.

The trickiest part is the neuromuscular distinction: SS causes clonus and hyperreflexia (especially in the lower extremities), while NMS causes 'lead-pipe' rigidity without clonus. MH is a completely separate beast — it's a pharmacogenetic disorder triggered by volatile anesthetics (halothane, isoflurane, desflurane) or succinylcholine, caused by a RYR1 mutation that causes uncontrolled calcium release from skeletal muscle. Students often blur MH with the other two because all three involve muscle pathology and fever. On USMLE Step 1, MH questions will have an OR/anesthesia setting — that context is almost always the giveaway.

Serotonin syndrome is triggered by serotonergic drug combinations — MAOI + SSRI, tramadol, linezolid, triptans, St. John's Wort. NMS is triggered by dopamine receptor blockade, classically typical antipsychotics or abrupt discontinuation of dopaminergic drugs (e.g., stopping levodopa). The treatment distinction is high yield: cyproheptadine (5-HT2 antagonist) and benzos for SS; dantrolene and bromocriptine for NMS; dantrolene alone for MH. A common student error is reaching for dantrolene for all three — that reflex will cost you points.

From real student decks
65%have cards covering this topic
43%have mature cards

Common misconceptions

Common mistake
Wrong: Both serotonin syndrome and NMS present with the same type of muscle rigidity.
Right: Serotonin syndrome causes hyperreflexia and clonus (lower extremity > upper), while NMS causes 'lead-pipe' rigidity without clonus.
The rigidity in SS and NMS looks similar on the surface but has a key mechanistic difference. Serotonin syndrome causes excess serotonergic activity at spinal cord level, producing hyperreflexia and clonus — especially ankle clonus — without the diffuse uniform resistance seen in NMS. NMS causes 'lead-pipe' rigidity from dopamine blockade in the basal ganglia, which produces a uniform, waxy resistance throughout the range of motion. If the vignette mentions clonus, that's SS; if it says lead-pipe or describes uniform rigidity without clonus, that's NMS.
Common mistake
Wrong: NMS is caused by too much dopamine activity, similar to how serotonin syndrome involves excess serotonin.
Right: NMS is caused by dopamine receptor blockade (e.g., antipsychotics), not excess dopamine.
NMS is caused by too little dopamine signaling, not too much. Antipsychotics block D2 receptors in the hypothalamus and striatum, disrupting thermoregulation and motor control. This is analogous to Parkinson's disease pathophysiology — loss of dopaminergic tone leads to rigidity. Think of NMS as 'iatrogenic dopamine deficiency' and you'll never confuse it with serotonin excess again.
Common mistake
Wrong: Malignant hyperthermia is triggered by the same drugs that cause NMS or serotonin syndrome.
Right: Malignant hyperthermia is triggered by volatile anesthetic agents (e.g., halothane, isoflurane) and succinylcholine, not antipsychotics or serotonergic drugs.
Malignant hyperthermia has nothing to do with neurotransmitter excess or receptor blockade — it's a pharmacogenetic disorder. Patients have a mutation in the RYR1 gene encoding the ryanodine receptor on the sarcoplasmic reticulum. When exposed to volatile anesthetic agents or succinylcholine, the receptor becomes stuck open, flooding skeletal muscle with calcium and causing uncontrolled contraction. If the question involves an OR setting with a volatile anesthetic or succinylcholine, MH is the answer regardless of whether the patient has psychiatric or serotonergic drug history.
Common mistake
Wrong: Dantrolene is the antidote for all three hyperthermic syndromes.
Right: Dantrolene is the treatment for malignant hyperthermia (and NMS in severe cases); serotonin syndrome is treated with cyproheptadine and benzodiazepines.
Dantrolene blocks the ryanodine receptor (RYR1) and prevents calcium release from the sarcoplasmic reticulum — that mechanism is directly relevant to MH and is why it's the first-line treatment. For NMS, dantrolene can help with the muscle rigidity component, but bromocriptine (a D2 agonist) addresses the underlying mechanism. For serotonin syndrome, dantrolene does nothing for the root cause; you need cyproheptadine (a 5-HT2 antagonist) to block excess serotonin activity, plus benzodiazepines for sedation and muscle relaxation.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a patient on multiple serotonergic medications who develops hyperthermia, agitation, clonus, and hyperreflexia, identify the diagnosis as serotonin syndrome and select the correct treatment (cyproheptadine, benzodiazepines).
  2. Given a patient started on a typical antipsychotic who develops hyperthermia, lead-pipe rigidity, altered consciousness, and autonomic instability, identify the diagnosis as NMS and recognize that dopamine receptor blockade — not excess dopamine — is the mechanism.
  3. Given a patient under general anesthesia who develops rapidly rising temperature, masseter rigidity, hypercapnia, and metabolic acidosis, identify malignant hyperthermia as the diagnosis, recognize halothane or succinylcholine as the trigger, and select dantrolene as treatment.

Can you avoid these mistakes?

A 28-year-old woman on phenelzine for depression is prescribed tramadol after a dental procedure. Two hours later she develops agitation, diaphoresis, tremor, and lower extremity clonus with hyperreflexia. Temperature is 39.4°C. What is the diagnosis, what is the mechanism, and what do you give her?
A 35-year-old man with schizophrenia is started on haloperidol. One week later he presents with 40.1°C fever, diffuse lead-pipe rigidity, confusion, and BP 160/100. Labs show elevated CK and WBC. What caused this, and how is the mechanism different from serotonin syndrome?
A 22-year-old with no known medical history undergoes elective surgery. Shortly after induction with succinylcholine and halothane, the anesthesiologist notices masseter spasm, rapidly rising end-tidal CO2, and temperature climbing to 41°C. What drug do you reach for first, and what is the molecular target of that drug?
A student says: 'I'll just remember to give dantrolene for any patient who is hyperthermic and rigid from a drug reaction.' Where does this reasoning fail, and for which syndrome would following this advice leave the underlying mechanism completely untreated?

Related topics

ADME and Bioavailability Volume of Distribution (Vd) Clearance and Half-Life First-Order vs Zero-Order Elimination

See how your Anki deck covers this topic.

Upload your deck for a free audit →